SEARCH TERMS
Suggested Terms

Want to better focus your search?
Upgrade to a account to unlock 5 additional filters (including Entity Type), search inside of entities, and more!
Which are the top organizations worldwide?
Top organizations by Linknovate score
Biocept
377.9 score | records 45
OncoCyte Corporation
222.9 score | records 29
Trovagene Inc.
209.3 score | records 20
Exosome Diagnostics
174.9 score | records 41
Where are the main hubs located?
What are the most relevant records?
Top records by Linknovate score

Patent
Yaya Diagnostics GmbH | Date: 2017-04-19

The present invention relates to means for and methods of collecting, enriching, and analyzing nucleic acids of interest of interest, e.g. those that are associated with the development of sepsis. These means may be used in vivo or in vitro using obtained nucleic acids of interest, e.g. for liquid biopsies. The invention can, inter alia, be used in the detection and enrichment as well as analysis of nucleic acids of interests such as those derived from pathogens or from individuals that may contain such pathogens.

...

News Article | May 19, 2017
Site: www.businesswire.com

LEWISVILLE, Texas--(BUSINESS WIRE)--med fusion, a Roche Molecular Center of Excellence and a leader in advanced laboratory diagnostics, is proud to announce the launch of their plasma based EGFR Liquid Biopsy service. The service utilizes Roche’s FDA-approved cobas® EGFR Mutation Test v2 to identify 42 mutations in the epidermal growth factor receptor (EGFR) gene, including T790M mutations, to help physicians select eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI). The EGFR Liquid Biopsy service augments med fusion’s existing decision support tools for physicians treating NSCLC patients, LungSEQ® and 50SEQ® Plus FISH. Using a simple blood draw, it provides a non-invasive alternative for EGFR mutation testing in NSCLC patients when tissue biopsies cannot be obtained or the available specimen is scarce. EGFR mutation status helps physicians determine which treatment options, e.g. EGFR TKIs, are likely to benefit patients with metastatic NSCLC. “ med fusion’s ultimate goal is to improve patient care by providing responsible precision medicine solutions,” said Jon Hart, med fusion’s Chief Executive Officer. “ Expanding our menu to include the EGFR Liquid Biopsy test helps us accomplish our goal by providing physicians with a reliable, non-invasive test to determine EGFR mutation status and related treatment options for their NSCLC patients when tissue biopsies are not available.” “ We’re honored that med fusion is using Roche’s test as the basis for their EGFR Liquid Biopsy service,” said Jack Phillips, President and CEO of Roche Diagnostics Corporation. “ This is a service that will benefit their network of physicians and the lung cancer patients they serve, and we are proud to be part of it.” med fusion, an integrated Roche Molecular Center of Excellence and clinical trials service organization, delivers support to healthcare providers and biotech/pharmaceutical companies. An industry leader in advanced laboratory diagnostics and support, our full service clinical laboratory includes a dedicated test development and validation team to meet the needs of clients and reference lab services such as pathology and molecular diagnostics. med fusion is committed to facilitate the realization of responsible precision medicine by specializing in: Oncology, Women’s Health, Urology, and Infectious Disease. Headquartered in Lewisville, Texas, med fusion offers its specialized services throughout the U.S. To learn more, please visit www.medfusionservices.com.

...
Linknovate helps you find your next partner or supplier
"Linknovate brought us in just 2 weeks a supplier we searched for 3 months"
Thomas Lackner, Director of Open Innovation
Upload content to Linknovate to showcase your work
Join hundreds of start-ups, universities, research labs and corporations that use Linknovate to market their capabilities and connect with new clients and partners.
How does the expertise of two organizations compare?
Organizations compared on records for related keywords
What’s the commercial readiness level of this field?
Evolution of record type per year
What kind of sources are most common?
Weight of records per source
Name Score Publications Conferences Grants Patents Trademarks News Webs
377.9 10 10 10 10 10 10 10
222.9 10 10 10 10 10 10 10
209.3 10 10 10 10 10 10 10
174.9 10 10 10 10 10 10 10
159.9 10 10 10 10 10 10 10
153.0 10 10 10 10 10 10 10
139.0 10 10 10 10 10 10 10
120.0 10 10 10 10 10 10 10
115.3 10 10 10 10 10 10 10
113.7 10 10 10 10 10 10 10
99.6 10 10 10 10 10 10 10
84.5 10 10 10 10 10 10 10
83.6 10 10 10 10 10 10 10
80.3 10 10 10 10 10 10 10
73.3 10 10 10 10 10 10 10
72.0 10 10 10 10 10 10 10
69.6 10 10 10 10 10 10 10
66.0 10 10 10 10 10 10 10
63.8 10 10 10 10 10 10 10
62.9 10 10 10 10 10 10 10
61.9 10 10 10 10 10 10 10
61.8 10 10 10 10 10 10 10
61.4 10 10 10 10 10 10 10
61.0 10 10 10 10 10 10 10
58.5 10 10 10 10 10 10 10
57.0 10 10 10 10 10 10 10
55.4 10 10 10 10 10 10 10
55.1 10 10 10 10 10 10 10
53.7 10 10 10 10 10 10 10
53.6 10 10 10 10 10 10 10
53.3 10 10 10 10 10 10 10
53.0 10 10 10 10 10 10 10
52.9 10 10 10 10 10 10 10
52.5 10 10 10 10 10 10 10
52.3 10 10 10 10 10 10 10
51.2 10 10 10 10 10 10 10
51.1 10 10 10 10 10 10 10
50.3 10 10 10 10 10 10 10
50.0 10 10 10 10 10 10 10
48.8 10 10 10 10 10 10 10
48.5 10 10 10 10 10 10 10
47.5 10 10 10 10 10 10 10
42.9 10 10 10 10 10 10 10
42.7 10 10 10 10 10 10 10
42.4 10 10 10 10 10 10 10
41.6 10 10 10 10 10 10 10
41.1 10 10 10 10 10 10 10
40.9 10 10 10 10 10 10 10
40.5 10 10 10 10 10 10 10
40.5 10 10 10 10 10 10 10
40.0 10 10 10 10 10 10 10
39.8 10 10 10 10 10 10 10
39.5 10 10 10 10 10 10 10
39.1 10 10 10 10 10 10 10
39.0 10 10 10 10 10 10 10
38.8 10 10 10 10 10 10 10
38.8 10 10 10 10 10 10 10
38.5 10 10 10 10 10 10 10
38.0 10 10 10 10 10 10 10
37.8 10 10 10 10 10 10 10
Cancer Research UK Research Institute
37.2 16 - - 10 10 10 10
Illumina
36.9 4 - - 10 10 10 10
Sysmex Inostics
36.4 - - - 10 10 10 10
Trovagene
36.3 - - - 10 10 10 10
Worcester Polytechnic Institute
36.0 4 - - 10 10 10 10
University of California at San Diego
35.7 8 - - 10 10 10 10
Chinese University of Hong Kong
35.1 8 - - 10 10 10 10
Molecular Diagnostics
34.8 - - - 10 10 10 10
Foundation Medicine
34.7 3 - - 10 10 10 10
Montpellier University
34.6 15 - - 10 10 10 10
Tumor Biology
34.6 - - - 10 10 10 10
University Pierre and Marie Curie
34.1 22 - - 10 10 10 10
MDNA Life science Inc.
34.0 - - - 10 10 10 10
American Cancer Society
33.9 - - - 10 10 10 10
Hoffmann-La Roche
33.2 4 - - 10 10 10 10
Cleveland Clinic
33.1 9 - - 10 10 10 10
ALK
33.0 - - - 10 10 10 10
University of Southern California
32.7 20 - - 10 10 10 10
Silicon Biosystems
32.0 - - - 10 10 10 10
Terumo BCT
31.9 - - - 10 10 10 10
Illumina Inc.
31.0 - - - 10 10 10 10
Helomics
31.0 - - - 10 10 10 10
Agena Bioscience
30.6 - - - 10 10 10 10
Science Translational Medicine
29.5 - - - 10 10 10 10
CRUK
29.5 - - - 10 10 10 10
Zomedica
29.1 - - - 10 10 10 10
Netherlands Cancer Institute
28.9 22 - - 10 10 10 10
Memorial Sloan Kettering
28.9 - - - 10 10 10 10
Grand Hyatt
28.9 - - - 10 10 10 10
University of California San Diego
28.8 - - - 10 10 10 10
AUA
28.5 - - - 10 10 10 10
Precipio Diagnostics
28.3 - - - 10 10 10 10
Facebook
28.1 - - - 10 10 10 10
Systems Laboratory
28.1 - - - 10 10 10 10
University of Twente
27.7 10 - 1 10 10 10 10
LinkedIn
27.6 - - - 10 10 10 10
Okayama University
27.6 6 - - 10 10 10 10
American Thoracic Society
27.5 - - - 10 10 10 10
University of Houston
27.4 23 - - 10 10 10 10
PMT
27.4 - - - 10 10 10 10

Patent
Yaya Diagnostics GmbH | Date: 2017-04-19

The present invention relates to means for and methods of collecting, enriching, and analyzing nucleic acids of interest of interest, e.g. those that are associated with the development of sepsis. These means may be used in vivo or in vitro using obtained nucleic acids of interest, e.g. for liquid biopsies. The invention can, inter alia, be used in the detection and enrichment as well as analysis of nucleic acids of interests such as those derived from pathogens or from individuals that may contain such pathogens.


News Article | May 19, 2017
Site: www.businesswire.com

LEWISVILLE, Texas--(BUSINESS WIRE)--med fusion, a Roche Molecular Center of Excellence and a leader in advanced laboratory diagnostics, is proud to announce the launch of their plasma based EGFR Liquid Biopsy service. The service utilizes Roche’s FDA-approved cobas® EGFR Mutation Test v2 to identify 42 mutations in the epidermal growth factor receptor (EGFR) gene, including T790M mutations, to help physicians select eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI). The EGFR Liquid Biopsy service augments med fusion’s existing decision support tools for physicians treating NSCLC patients, LungSEQ® and 50SEQ® Plus FISH. Using a simple blood draw, it provides a non-invasive alternative for EGFR mutation testing in NSCLC patients when tissue biopsies cannot be obtained or the available specimen is scarce. EGFR mutation status helps physicians determine which treatment options, e.g. EGFR TKIs, are likely to benefit patients with metastatic NSCLC. “ med fusion’s ultimate goal is to improve patient care by providing responsible precision medicine solutions,” said Jon Hart, med fusion’s Chief Executive Officer. “ Expanding our menu to include the EGFR Liquid Biopsy test helps us accomplish our goal by providing physicians with a reliable, non-invasive test to determine EGFR mutation status and related treatment options for their NSCLC patients when tissue biopsies are not available.” “ We’re honored that med fusion is using Roche’s test as the basis for their EGFR Liquid Biopsy service,” said Jack Phillips, President and CEO of Roche Diagnostics Corporation. “ This is a service that will benefit their network of physicians and the lung cancer patients they serve, and we are proud to be part of it.” med fusion, an integrated Roche Molecular Center of Excellence and clinical trials service organization, delivers support to healthcare providers and biotech/pharmaceutical companies. An industry leader in advanced laboratory diagnostics and support, our full service clinical laboratory includes a dedicated test development and validation team to meet the needs of clients and reference lab services such as pathology and molecular diagnostics. med fusion is committed to facilitate the realization of responsible precision medicine by specializing in: Oncology, Women’s Health, Urology, and Infectious Disease. Headquartered in Lewisville, Texas, med fusion offers its specialized services throughout the U.S. To learn more, please visit www.medfusionservices.com.


One of the biggest obstacles to surviving cancer is the way the disease can shift its shape and form over time. Tumours are diverse and contain cells of many different types, with different genetic and epigenetic make-up. This allows cancer to adapt to changing environments, survive treatments and spread. Researchers want to combat this fundamental lethal property to improve treatment. But to study tumour evolution in this way is to chase a fast-moving target. Investigators must track the genetic shifts in cancer cells in real time by setting up prospective assays that sample and analyse tumours during therapy. In theory, it should then be possible to tailor a growing arsenal of cancer drugs to fight emerging patterns of resistance and relapse. But finding a way to do this in the least invasive way represents a formidable challenge — and one that lies beyond the reach of existing tissue biopsies. There is another way. Over the past few years, interest has grown in developing techniques to analyse cell-free DNA in the blood, such as prenatal genetic testing for fetal DNA in the mother’s bloodstream. As cancer takes hold, the blood fills with free-floating DNA released from dying tumour cells. These genetic fragments could be used to check on the evolution of the tumours they came from. And in a promising clinical study published this week by Nature (C. Abbosh et al. Nature http://dx.doi.org/10.1038/nature22364; 2017), scientists report how they have done just that. What’s more, their trial design — incorporating prospective observations of these circulating fragments of cancer DNA — is a step towards implementing tumour-evolution monitoring as a clinical tool that can dynamically inform treatment. The clinical data reported online in Nature, and in a parallel paper in the New England Journal of Medicine (M. Jamal-Hanjani et al. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1616288; 2017), describe the results from the first 100 patients enrolled in a trial called TRACERx, which aims to follow the tumour evolution of people with lung cancer who are undergoing therapy. The Nature paper describes a test to assess and compare genetic changes in tumours and in the blood. The dynamic tracking made possible by this “liquid biopsy” sequencing shows that early recurrence of the disease can be detected, and is associated with identifiable features in the circulating tumour DNA. The results of the analysis support the idea that such liquid biopsies could provide clinical benefit by simplifying procedures and allowing for more-intensive real-time monitoring. Clinical implementation requires additional long-term studies, so that the performance of this type of monitoring can be tested alongside therapy. This is starting to happen: the design of clinical cancer trials is evolving rapidly to accommodate biomarker testing, and a growing number of registered trials are in progress to prospectively monitor tumour progression in the blood. Still, some challenges remain, including the feasibility and cost of routinely applying liquid-biopsy techniques in clinical practice. Besides helping to guide clinical decisions, the information derived from close monitoring of tumours with liquid biopsies can be readily fed back to the cancer-research pipeline. Investigators can use this information to work out the mechanism behind the remarkable plasticity of tumours, and translational colleagues could then build on these insights to provide clinicians with improved cancer-killing drugs. Nature is pleased to bring to our audience this type of clinical study. Such research should not only help convert research findings into medicines, but also provide a wealth of information for basic and clinical scientists. We hope such papers will continue to foster collaboration, and to bridge the gaps between basic and clinical points of view. As they align their sights to parse DNA fragments in the blood, researchers of all types can learn more from patients about how to help them more effectively.


Patent
Epic Sciences, Inc. | Date: 2017-08-23

The disclosure provides a method for determining if a subject afflicted with cancer is a candidate for Programmed Death Ligand-1 (PD-Ll) targeted immunotherapy, which method comprises (a) providing a liquid biopsy sample obtained from the subject afflicted with cancer; (b) detecting CTCs in the liquid biopsy sample; (c) calculating what proportion of CTCs in the liquid biopsy express PD-Ll; and (c) identifying the subject as a candidate for PD-Ll targeted immunotherapy based on an assessment that the proportion of the CTCs in the liquid biopsy that express PD-Ll exceeds a pre-determined threshold level.

Claims which contain your search:

1. A method for determining if a subject afflicted with cancer is a candidate for Programmed Death Ligand-1 (PD-Ll) targeted immunotherapy, which method comprises (a) providing a liquid biopsy sample obtained from the subject afflicted with cancer; (b) detecting CTCs in the liquid biopsy sample; (c) calculating what proportion of CTCs in the liquid biopsy express PD-Ll; and (c) identifying the subject as a candidate for PD-Ll targeted immunotherapy based on an assessment that the proportion of the CTCs in the liquid biopsy that express PD-Ll exceeds a pre-determined threshold level.

4. The method of claim 1, further comprising identification of white blood cells (WBCs) in the liquid biopsy sample.

6. The method of claim 5, further comprising enumeration of WBCs in the liquid biopsy sample.

12. The method of claim 9, comprising communicating that the subject was not identified as a candidate based on the assessment that the proportion of CTCs in the liquid biopsy that express PD-Ll is below a predetermined threshold level.

16. A method of monitoring expression of PD-Ll on circulating tumor cells (CTCs) of a subject undergoing PD-Ll targeted immunotherapy, which method comprises (a) providing at least two liquid biopsy samples from the subject undergoing PD-Ll targeted immunotherapy, wherein the samples were obtained at separate pre-determined time points; (b) detecting CTCs in the liquid biopsy samples; (c) calculating what proportion of CTCs in the liquid biopsy samples express PD-Ll; and (c) comparing the proportion of CTCs that express PD-Ll between the liquid biopsy samples to monitor the expression of PD-Ll .

20. A method for determining whether a determining if a subject afflicted with cancer is at risk for metastasis, which method comprises (a) providing a liquid biopsy obtained from the subject afflicted with cancer; (b) detecting CTCs that express PDL-1 in the liquid biopsy sample; (c) calculating what proportion of CTCs in the liquid biopsy express PD-Ll are CK-negative; and (c) identifying the subject as a candidate at risk for metastasis based on an assessment that the proportion of CK-negative CTCs in the liquid biopsy that express PD-Ll exceeds a predetermined threshold level.


Patent
Medcom Advance S.A., Medcom Technology S.A. and Fundacion Of Investigacion Hm Hospitales | Date: 2017-09-06

The invention relates to an apparatus and method of detecting and quantifying the number of circulating tumour cells (CTCs) and/or tumour cells (TCs) from a liquid biopsy by using a hyperoxic environment and incubation with a fluorophore-labelled metabolic indicator (fluorophore-labelled 2-D-glucose derivative) and microfluidic chips.

Claims which contain your search:

8. A microfluidic chip selected from the group consisting of:a) a mixing chip comprising(i) at least two inlets, wherein one inlet is for introducing a liquid sample and the other inlet(s) is/are for introducing a solution comprising a fluorophore-labelled metabolic indicator saturated with oxygen or components thereof, all the inlets converging in a micromixer for the mixture and incubation of the liquid sample and the solution comprising a fluorophore-labelled metabolic indicator saturated with oxygen, and(ii) an outlet to allow the exit of the mixture to a purification chip;b) a purification chip comprising(i) an inlet for the entrance of a mixture,(ii) a main microchannel with constrictions and lateral bifurcation microchannels for the extraction of the fluorophore-labelled metabolic indicator not accumulated in cells while avoiding the removal of cells,(iii) a main microchannel outlet for the exit of cells to the detection chip, and(iv) further lateral bifurcation outlets for the exit of the extracted fluorophore-labelled metabolic indicator; andc) a detection chip comprising three inlets, a first central inlet for the entrance of cells and the second and third inlets for the entrance of a solution for cell focusing, wherein the second and third inlets are situated at opposite sides of the first central inlet, all the inlets converging into a single microchannel which is optionally widen for being used as inspection region in the detection of stained cells by fluorescence, and an outlet for the exit of the mixture of cells and the solutionor a set of microfluidic chips consisting of at least two microfluidic chips selected from a), b) and c).

1. An in vitro method for the detection of a circulating tumour cell (CTC) and/or a tumour cell (TC) in a liquid sample comprising the steps of:a) optionally, culturing the liquid sample in a cell culture medium;b) incubating the cells contained in the liquid sample or the cells obtained in step a) with a solution supplemented with a fluorophore-labelled metabolic indicator and saturated with oxygen, and during an appropriate time to allow the CTCs/TCs to accumulate the fluorophore-labelled metabolic indicator;c) removing the excess of the fluorophore-labelled metabolic indicator not accumulated in cells; andd) measuring the fluorescence of the fluorophore-stained cellswherein the detection of a fluorophore-stained cell having a fluorescence intensity superior to a control cell indicates the presence of a CTC/TC in the liquid sample.

15. Use of a fluorophore-labelled metabolic indicator for the detection and/or quantification of CTCs/TCs in a liquid sample.

14. Use of the device according to any one of claims 7 or 9 to 12, or the microfluidic chip or set of microfluidic chips according to any one of claims 8 or 9 to 12, or the kit according to claim 13 for the detection and/or quantification of CTCs/TCs in a liquid sample; or for CTCs/TCs sorting, isolating or capturing.

7. A device comprising a set of microfluidic chips for the detection of circulating tumour cells (CTCs) and/or tumour cells (TCs) in a liquid sample comprising:a) a mixing chip comprisingi. at least two inlets, wherein one inlet is for introducing the liquid sample and the other inlet(s) is/are for introducing a solution comprising a fluorophore-labelled metabolic indicator saturated with oxygen or components thereof, all the inlets converging in a micromixer for the mixture and incubation of the liquid sample and the solution comprising a fluorophore-labelled metabolic indicator saturated with oxygen, andii. an outlet to allow the exit of the mixture to the purification chip;b) a purification chip comprisingi. an inlet for the entrance of the mixture,ii. a main microchannel with constrictions and lateral bifurcation microchannels for the extraction of the fluorophore-labelled metabolic indicator not accumulated in cells while avoiding the removal of cells,iii. a main microchannel outlet for the exit of cells to the detection chip, andiv. further lateral bifurcation outlets for the exit of the extracted fluorophore-labelled metabolic indicator; andc) a detection chip comprising three inlets, a first central inlet for the entrance of cells and the second and third inlets for the entrance of a solution for cell focusing, wherein the second and third inlets are situated at opposite sides of the first central inlet, all the inlets converging into a single microchannel which is optionally widen for being used as inspection region in the detection of stained cells by fluorescence, and an outlet for the exit of the mixture of cells and the solution.


News Article | June 30, 2017
Site: www.eurekalert.org

Barcelona, Spain, 30 June 2017 - A new study, to be presented at the ESMO 19th World Congress on Gastrointestinal Cancer, shows that so-called "liquid biopsies", blood tests that detect circulating tumour DNA (ctDNA), may not only sound an early alert that a treatment's effect is diminishing, but may also help explain why -sometimes offering clues about what to do next. Why a cancer treatment is losing its effectiveness, is a question that preoccupies every patient and their doctor. But checking in on a drug's tumor-fighting progress is not easy - usually involving invasive biopsies and expensive scans. "We have shown that integrating regular liquid biopsies into our patients' routine care is feasible and easily incorportated into clinical practice," said study investigator Aparna Parikh, MD, from Massachusetts General Hospital Cancer Center, in Boston, Massachusetts. "This technology can precisely help us understand each patient's indvididual disease course and allows us to tailor care based on an understanding of their specific disease biology," she said. In fact, compared to standard tissue biopsies, which can be painful and difficult to obtain, her study showed that liquid biopsies actually provided more information less invasively. The study involved nearly 40 patients with various forms of gastro-intestinal (GI) cancers, who had initially responded to therapy but then stopped. Liquid biopsies were done when their disease began to progress and ctDNA in the blood was analysed for genetic mutations that might be making them resistant to treatment. A total of 31 patients had at least one such mutation, and among them,14 had more than one. Notably in about two thirds of patients who had traditional tissue biospies taken at the same time, the liquid biopsy picked up extra mutations that could not be seen in the tissue. "Identifying what specific mutations are responsible for treatment resistance is very important in helping clinicians choosing what treatment path a patient should try next, whether it be another drug or perhaps radiation," explained Parikh. While liquid biopsies are not yet widely used outside of the research setting, Parikh believes they are set to transform cancer treatment. "We have shown this approach is feasible across many different GI cancers," she noted. "The next step is to study how best to use this new technology in daily practice. It's important for clinicians to understand its utility as well as its limitations." Commenting on the study, ESMO spokesperson Frederica Di Nicolantonio, MD, from the Candiolo Cancer Institute and University of Torino in Italy said, "this work elegantly reports that the use of clinical liquid biopsy panels can effectively identify multiple heterogeneous and co-occuring mechanisms of acquired drug resistance, all in a non-invasive manner. Clinicians should be able to better individualise patient care based on results from this technology." 1. Abstract O-001 - 'Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients' will be presented by Dr Aparna Parikh during 'Session X: Presentation of Selected Abstracts - Colorectal Cancer' on Friday, 30 June, 08:40 to 09:45 (CEST) in Auditorium B. This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct. The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours. ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment. Imedex is an industry leader in providing accredited, independent continuing medical education to health care professionals. We develop high quality scientific programming that translates the latest research into clinically relevant information. The activities have exceptional organization and outstanding educational value, with a proven sustained impact on disease management. Our programs focus on improving patient care around the world. With over 50,000 e-learning experiences annually and more than 100,000 live meeting attendees, since 2001, Imedex truly educates the global healthcare community. At Imedex, education is the best medicine®.


The present invention relates to methods of using cell-free DNA analysis for guiding treatment of advanced prostate cancer. In particular, liquid biopsies are collected from urine and/or plasma of patients for measuring copy number variation in cell-free DNA associated with metastatic prostate cancer. In particular, urine genomic abnormality (UGA) and plasma genomic abnormality (PGA) values are contemplated for use in predicting treatment responses in advanced prostate cancer patients and for use in making decisions related to androgen deprivation therapy (ADT) treatment outcomes in hormone sensitive stage and for starting or changing chemotherapy treatments in castrate resistant advanced cancer stage.


News Article | June 27, 2017
Site: www.prnewswire.com

"These important findings confirm what thousands of Guardant360-ordering physicians have experienced in their clinics," said Dr. Richard Lanman, Guardant Health's Chief Medical Officer. "When Guardant360 results are used to guide treatment decisions patients respond to matched therapy at the expected rates, while avoiding repeat invasive biopsies." The study "Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities" appeared in Clinical Lung Cancer, while "Prospective Feasibility-Study for Utilizing Cell-free Circulating Tumor DNA Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis" appeared in JCO Precision Oncology. Genomic testing in advanced lung cancer can help doctors match their patients to targeted therapies that may be less toxic than traditional chemotherapy. But logistical issues associated with obtaining these results can limit the number of patients who receive even the most basic genomic testing, the authors of the Clinical Lung Cancer paper found. Clinicians often find it difficult to perform the recommended testing for EGFR, ALK, and other drug target alterations because there is either a complete lack of tissue or insufficient tissue from a biopsy. Less than 60 percent of patients in the study met the guideline recommendations for EGFR and ALK testing, and only 8 percent were tested for alterations in all seven genes included in the NCCN NSCLC guidelines. "The guidelines recommend broad genomic testing in all patients with advanced non-small cell lung cancer, but adherence is often impractical in the community setting because of the challenges of working with small tissue biopsies," said Martin Gutierrez, head of thoracic oncology at John Theurer Cancer Center, and lead author on the study. "Less invasive, comprehensive testing with the Guardant360 assay could help with guideline adherence, and ensure that all patients are being evaluated for a possible targeted therapy option instead of chemotherapy. This is something we've observed in our own practice." For the JCO Precision Oncology study, researchers from the Samsung Medical Center in Seoul prospectively enrolled 194 patients with advanced lung, gastric, and other solid cancers and measured their response to treatment that was selected based on Guardant360 results. Patients responded to the matched therapies at expected rates, the study found. The Guardant360 assay is the most validated comprehensive liquid biopsy and was the first to be commercially introduced in 2014. It examines tiny fragments of circulating tumor DNA (ctDNA) that are released into the blood stream by dying tumor cells, and can provide advanced cancer patients a genomic profile of their cancer without requiring an invasive biopsy. The test is now the most widely used comprehensive liquid biopsy and has been ordered more than 40,000 times by more than 3,500 oncologists. About Guardant Health Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. Using both molecular and digital tools, Guardant Health is addressing challenges across the cancer care continuum. The company has raised more than $500 million from leading investors. Its first product, the Guardant360 assay, came to market in 2014, and is now the most widely ordered comprehensive liquid biopsy commercially available. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease. Guardant Health and Guardant360 are registered trademarks of Guardant Health, Inc. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-studies-demonstrate-the-need-for-and-utility-of-comprehensive-liquid-biopsies-300480426.html


News Article | July 13, 2017
Site: www.prnewswire.com

LONDON, July 12, 2017 /PRNewswire/ -- Report Details Liquid Biopsies – our new study reveals trends, R&D progress, and predicted revenues Where is the liquid biopsy market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Download the full report: https://www.reportbuyer.com/product/4753862/ Discover How to Stay Ahead Our 205-page report provides 190 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing liquid biopsy market. See how to exploit the opportunities. Forecasts to 2027 and other analyses reveal the commercial prospects - In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. - You find original analyses, with business outlooks and developments. - Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, you find revenue forecasts for 4 different segmentations of the market, including forecasts for 3 sample types, 3 biomarker types, 7 applications and 4 end users: - Liquid biopsy Market Forecasts to 2027, By Sample Type - Blood - Urine - Other - Liquid biopsy Technologies Market Forecasts to 2027, By Biomarker Type - CTC - ctDNA - Exosomes - Liquid biopsy Technologies Market Forecasts to 2027, By Application - Lung Cancer - Gastrointestinal Cancer - Breast Cancer - Colorectal Cancer - Leukaemia - Prostate Cancer - Other Cancers - Liquid biopsy Technologies Market Forecasts to 2027, By End User - Hospitals - Academic Institutes - Diagnostic Laboratories - Cancer Research Centres In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts 5 leading regional markets and 19 leading national markets: - North America - US - Canada - Europe - Germany - France - UK - Italy - Spain - Russia - Rest of Europe - APAC - Japan - China - India - South Korea - Singapore - Australia & New Zealand - Rest of APAC - Latin America - Brazil - Argentina - Rest of Latin America - MEA - GCC - South Africa - Rest of MEA There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market. Leading companies and the potential for market growth Overall world revenue for liquid biopsy will surpass $0.4bn in 2017, our work calculates. We predict strong revenue growth through to 2027. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the Liquid biopsy Technologies Market report helps you In summary, our 204-page report provides you with the following knowledge: - Revenue forecasts to 2027 for the world liquid biopsy market and 4 different segmentations, with 3 sample types, 3 biomarker types, 7 applications and 4 end-user types – discover the industry's prospects, finding the most lucrative places for investments and revenues - Revenue forecasts to 2027 for the leading 5 regional and 19 national markets – North America (US, Canada), Latin America (Brazil, Argentina, Rest of Latin America), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), APAC (Japan, China, India, South Korea, Singapore, Australia & New Zealand and Rest of APAC), MEA (GCC, South Africa and Rest of MEA) - Discussion of what stimulates and restrains companies and the market - Prospects for established firms and those seeking to enter the market Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight. Download the full report: https://www.reportbuyer.com/product/4753862/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com


Dublin, Aug. 15, 2017 (GLOBE NEWSWIRE) -- The "Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030" report has been added to Research and Markets' offering. The Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030' report provides an extensive study on liquid biopsy kits/assays that are either commercialized or are under development for diagnosis and/or monitoring of different types of cancer. The market is characterized by the presence of several companies that have proprietary technologies/platforms for either isolation/enrichment/enumeration of CTCs or for molecular characterization/sequencing of the genetic material extracted from the CTCs/exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, and patient and recurrence monitoring of different cancer indications. Such kits are likely to transform the cancer diagnostics market with many commercial success stories in the near future. The market is primarily led by start-ups/small companies, such as (in alphabetical order) CellMax Life, Celsee Diagnostics, Datar Genetics, DiaDx, EONE-DIAGNOSTICS Genome Center, Exosome Sciences, iCellate Medical, Inivata, IVDiagnostics, LCM Genect and MDNA Life Sciences. It also has presence of mid to large-sized pharma players; notable examples include (in alphabetical order) Biocartis, Counsyl, Foundation Medicine, Genomic Health and NeoGenomics Laboratories. In addition to the aforementioned players, a number of pharma giants are also developing assets in this field. Prominent players under this category include (in alphabetical order) Affymetrix, Menarini Silicon Biosystems, Myriad Genetics, QIAGEN, Roche, Siemens Healthineers and Thermo Fisher Scientific. As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives of this report was to understand the future potential of the market. In addition, we have provided a comprehensive market estimation to determine the global evolution of the liquid biopsy market. This has been done by evaluating the likely success of key applications of early diagnosis, recurrence monitoring and patient monitoring. We have included insights on the likely regional evolution of the market covering US, EU5 and rest of the world. In addition, we have estimated the likely contribution of different target patient populations to the global market; this covered key indications including (in alphabetical order) bladder cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer. Further, we segmented the market by the type of markers (CTCs, ctNAs, exosomes) and the sample source (blood, urine, saliva) used in different liquid biopsies. In order to account for uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios for the time period 2017-2030. The conservative, base and optimistic scenarios represent three different tracks of the industry's evolution. The research, analysis and insights presented in this report are backed by the deep understanding of key insights gathered from both secondary and primary research. 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Cancer Statistics and Burden of the Disease 3.3. Importance of Early Detection in Cancer 3.4. Detecting Cancer: Screening vs. Diagnosis 3.5. Conventional Invasive Cancer Diagnostic Tests 3.5.1. Biopsy 3.5.1.1. Fine Needle Aspiration Biopsy 3.5.1.2. Core Needle Biopsy 3.5.1.3. Vacuum-Assisted Biopsy 3.5.1.4. Image-Guided Biopsy 3.5.1.5. Sentinel Node Biopsy 3.5.1.6. Surgical Biopsy 3.5.1.7. Endoscopic Biopsy 3.5.1.8. Bone Marrow Biopsy 3.5.2. Endoscopy 3.6. Need for Non-Invasive Approaches 3.7. Costs and Benefits Associated with Non-Invasive Tests 4. CONCEPT OF NON-INVASIVE CANCER SCREENING AND DIAGNOSTICS 4.1. Chapter Overview 4.2. Diagnostic Imaging 4.2.1. Magnetic Resonance Imaging (MRI) 4.2.2. Mammography 4.2.3. Bone Scan 4.2.4. Computerized Tomography (CT) Scan 4.2.5. Integrated PET-CT Scan 4.2.6. Ultrasound 4.2.7. Barium Enema 4.3. Screening Assays 4.3.1. Papanicolaou Test (Pap Test) and Human Papilloma Virus Test (HPV Test) 4.3.2. Tumor Marker Test 4.3.3. Fecal Occult Blood Tests (FOBT) 4.3.4. Digital Rectal Exam (DRE) 4.3.5. Multigated Acquisition (MUGA) Scan 4.4. Advanced Non-Invasive Approaches 4.4.1. Liquid Biopsy 4.4.2. Cytogenetic/Gene Expression Studies 4.4.3. Molecular Signature Based Non-Invasive Methods 4.4.4. Saliva-Based Oral Cancer Diagnostics 4.4.5. Vital Staining 4.4.6. Optical Biopsy 4.4.7. Other Techniques 5. MARKET LANDSCAPE 5.1. Chapter Overview 5.2. Liquid Biopsy : Development Landscape 5.2.1. Liquid Biopsy Tests: Distribution by Development Stage 5.2.2. Liquid Biopsy Tests: Distribution by Sample Type 5.2.3. Liquid Biopsy Tests: Distribution by Type of Markers Detected 5.2.4. Liquid Biopsy Tests: Distribution by Indication 5.2.5. Liquid Biopsy Tests: Distribution by Type of Application 5.2.6. Liquid Biopsy Tests: Distribution by Geographical Coverage 5.2.7. Liquid Biopsy Tests: Distribution by Leading Players 5.3. Liquid Biopsy : Technologies, Platforms, Systems and Instruments 6. LIQUID BIOPSY MARKET: KEY INSIGHTS 6.1. Chapter Overview 6.2. Liquid Biopsy Tests: Competitive Landscape of Developers 6.3. Liquid Biopsy Tests: Distribution by Application and Target Indications 6.4. Emerging Trends on Non-Invasive Cancer Diagnostics on Social Media 6.4.1. Non-Invasive Cancer Diagnostics: Historical Trends by Twitter Volume (2010-2016) 6.4.2. Non-Invasive Cancer Diagnostics: Twitter Word Cloud (2010, 2012, 2014, 2016) 6.4.3. Non-Invasive Cancer Diagnostics: Twitter Trends for Popular Indications (2010-2016) 6.4.4. Non-Invasive Cancer Diagnostics: Twitter Trends for Samples Types (2010-2016) 7. LIQUID BIOPSY: DETAILED OUTLOOK 7.1. Chapter Overview 7.2. Non-Invasive Methods Over Biopsies for Detection of Cancer 7.3. Circulating Biomarkers for Cancer 7.3.1. Circulating Tumor Cells (CTCs) 7.3.1.1. Advantages Associated with the Use of CTCs 7.3.1.2. Challenges Associated with the Use of CTCs 7.3.2. Circulating Tumor DNA (ctDNA) 7.3.3. Exosomes 7.4. Liquid Biopsy Based Tests and Systems 7.4.1. BioFluidica CTC Isolation Technology, CTC Analysis System and Test, BioFluidica/Roche 7.4.2. CancerIntercept Detect and CancerIntercept Monitor, Pathway Genomics 7.4.3. Cancertrack, Datar Genetics 7.4.4. CellMax-LBx Liquid Biopsy and CellMax-CRC Colorectal Cancer Blood Test, CellMax Life 7.4.5. CELLSEARCH System and CELLSEARCH CTC Test, Menarini Silicon Biosystems 7.4.6. cobas EGFR Mutation Test v2, Roche 7.4.7. Liquid Biopsy Rare Cell Isolation Platform, ClearID Total Insight Breast Cancer, ClearID Lung Cancer and Clear ID Melanoma, Cynvenio Biosystems 7.4.8. Oncocount, Oncotrace, Oncotrial and Metastat, R.G.C.C. Group 7.4.9. OncoBEAM CRC RAS Kit, Sysmex Inostics/Merck 7.4.10. OnTarget Assay, Boreal Genomics 7.4.11. PrediSeq-Prostate and PrediSeq-Lung, Predicine 7.4.12. SelectMDx, MDxHealth 7.4.13. ViewRNA CTC Platform and Assay, Affymetrix 7.4.14. Velox, IVDiagnostics 7.4.15. ApoStream System and Technology, ApoCell 7.4.16. IsoPic, iCellate Medical 7.4.17. Parsortix System, ANGLE 7.5. Companion Liquid Biopsies: Recent Developments 7.5.1. Biocept and Baylor College of Medicine 7.5.2. Tokai Pharmaceuticals and QIAGEN 7.5.3. ANGLE and MD Anderson Cancer Center 7.5.4. AstraZeneca and QIAGEN 7.5.5. Sysmex Inostics and Bayer Healthcare 8. VENTURE CAPITAL FUNDING 8.1. Chapter Overview 8.2. Types of Funding 8.3. Liquid Biopsy Market: Funding Instances, 2011-2017 8.4. Liquid Biopsy Market: Distribution by Year 8.5. Liquid Biopsy Market: Distribution of Type of Model 8.6. Leading Players: Distribution by Funding Instances 9. COMPANY VALUATION ANALYSIS 9.1. Chapter Overview 9.2. Company Valuation: Methodology 9.3. Company Valuation: Categorization by Multiple Parameters 9.3.1. Categorization by Google Hits Score 9.3.2. Categorization by Awards Score 9.3.3. Categorization by Twitter Score 9.3.4. Categorization by Twitter Followers Score 9.3.5. Categorization by Number of Products 9.3.6. Categorization by Uniqueness Score 9.3.7. Categorization by Weighted Average Score 10. LIQUID BIOPSY: KEY PLAYERS 10.1. Chapter Overview 10.2. Biocartis 10.2.1. Company Overview 10.2.2. Financial Performance 10.2.3. Product Portfolio 10.2.3.1. Idylla ctBRAF Mutation Assay (RUO) 10.2.3.2. Idylla ctKRAS Mutation Assay 10.2.3.3. Idylla ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO) 10.3. Biocept 10.3.1. Company Overview 10.3.2. Financial Performance 10.3.3. Product Portfolio 10.3.3.1. Target Selector Breast Cancer Test 10.3.3.2. Target Selector Lung Cancer Test 10.3.3.3. Target Selector Immuno-Oncology PD-L1 Test 10.3.3.4. Target Selector Gastric Cancer Test 10.3.3.5. Target Selector Colorectal Cancer Test 10.3.3.6. Target Selector Prostate Cancer Test 10.3.3.7. Target Selector Melanoma Test 10.4. Biodesix 10.4.1. Company Overview 10.4.2. Financial Information 10.4.3. Product Portfolio 10.4.3.1. GeneStrat 10.4.3.2. VeriStrat 10.5. Exosome Diagnostics 10.5.1. Company Overview 10.5.2. Financial Information 10.5.3. Product Portfolio 10.5.3.1. ExoDx Prostate (IntelliScore) 10.5.3.2. ExoDx Lung (ALK) 10.5.3.3. ExoDx Lung (EGFR/T790M) 10.5.3.4. ExoDx Solid Tumor 10.6. Genomic Health 10.6.1. Company Overview 10.6.2. Financial Performance 10.6.3. Product Portfolio 10.6.3.1. Oncotype SEQ Liquid Select 10.7. Guardant Health 10.7.1. Company Overview 10.7.2. Financial Information 10.7.3. Product Portfolio 10.7.3.1. Guardant360 10.8. NeoGenomics Laboratories 10.8.1. Company Overview 10.8.2. Financial Performance 10.8.3. Product Portfolio 10.8.3.1. NeoLAB HEME 10.8.3.2. NeoLAB Solid Tumor Monitor (NeoLAB SOLID TUMOR) 10.8.3.3. NeoLAB Prostate 10.8.3.4. NeoLAB EGFR T790M Liquid Biopsy 10.9. Personal Genome Diagnostics (PGDx) 10.9.1. Company Overview 10.9.2. Financial Information 10.9.3. Product Portfolio 10.9.3.1. MetDETECT 10.9.3.2. PlasmaSELECT R 64 10.9.3.3. LungSELECT 10.10. QIAGEN 10.11. Transgenomic 10.12. Trovagene 11. OTHER NON-INVASIVE CANCER DIAGNOSTICS 11.1. Chapter Overview 11.2. Non-Blood Based Biomarker Detection Tests 11.3. DNA Methylation Detection Tests 11.4. Fecal Occult Blood Test (FOBT) AND Fecal Immunochemical Test (FIT) 11.5. MicroRNA (miRNA) Based Test 11.6. Pigmented Lesion Assay 11.7. Stool DNA (sDNA) Testing 11.8. Volatile Organic Compound (VOC) Detection Test 11.9. Other Non-Invasive Cancer Diagnostics: Market Landscape 11.10. Other Non-Invasive Cancer Diagnostics: Survey Analysis 11.10.1. Survey Analysis: Seniority Level of Respondents 11.10.2. Survey Analysis: Type of Product Portfolio 11.10.3. Survey Analysis: Types of Products/Services Offered 11.10.4. Survey Analysis: Type of Application 11.10.5. Survey Analysis: Availability of the Products 11.10.6. Survey Analysis: Likely Market Size 12. MARKET SIZING AND FORECAST 12.1. Chapter Overview 12.2. Forecast Assumptions and Methodology 12.3. Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030 12.3.1. Liquid Biopsy Market Forecast, 2017-2030 12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030 13. CONCLUSION 13.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care in the Field of Oncology 13.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer Management 13.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis 13.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range of Applications 13.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different Geographies 13.6. In Addition to Liquid Biopsy , Development of Other Non-Invasive Tests will Further Strengthen the Ongoing Innovation 13.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential 13.8. Primarily Led by Liquid Biopsy , The Non-Invasive Cancer Diagnostics Market has Emerged as a Multi-Billion Dollar Market 14. INTERVIEW TRANSCRIPTS 14.1. Chapter Overview 14.2. Burkhard Jansen, MD, Chief Medical Officer, DermTech 14.3. Frank Szczepanski, President and CEO, IVDiagnostics 14.4. Riccardo Razzini, Sales and Marketing Manager, LCM Genect 14.5. Nathalie Bernard, Marketing Director, OncoDNA 14.6. Abizar Lakdawalla, Founder, ProXeom 14.7. Mark Li, CEO, Resolution Bioscience 14.8. Christer Ericsson, Chief Scientific Officer, iCellate Medical 14.9. Philippe Nore, CEO and Co-founder, MiNDERA 14.10. Jake Micallef, Chief Scientific Officer, VolitionRx 15. APPENDIX 1: TABULATED DATA 16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS For more information about this report visit https://www.researchandmarkets.com/research/sdm2rg/noninvasive